This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: July 31, 2007
Last updated: March 24, 2017
Last verified: March 2017
An open-label, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermatitis in a daily practice

Condition Intervention Phase
Atopic Dermatitis Drug: Pimecrolimus Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • To evaluate the effectiveness of pimecrolimus cream 1% in the long-term management in mild to moderate atopic dermatitis in pediatric patients in a daily practice, as assessed by: • Investigator Global Assessment • Facial Investigator Global Ass

Secondary Outcome Measures:
  • • To monitor the safety of pimecrolimus cream 1% in the long-term management as assessed by Adverse Events and Serious Adverse Events collection • To evaluate quality of life of both parent and patient assessed by questionnaire. • To determine ste

Estimated Enrollment: 200
Study Start Date: April 2005
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Pimecrolimus
    Pimecrolimus cream 1 %
    Other Name: Elidel

Ages Eligible for Study:   3 Months to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 3 months to 12 years old
  • Clinical diagnosis of atopic dermatitis
  • History of mild to moderate atopic dermatitis
  • Investigator Global Assessment ≥ 1 (almost clear/clear of disease)
  • Written informed consent

Exclusion Criteria:

  • Investigator Global Assessment ≥ 4 (severe/very severe disease)
  • Patients with active skin viral infections (i.e, herpes simplex, herpes zoster, varicella)
  • Patients with atopic dermatitis, with active clinical infection on area of disease. All active infections must be treated prior to trial inclusion
  • Patients in an Immunosuppressive state or with history of malignant disease
  • Patients with clinical conditions other that Atopic Dermatitis that according to the investigator may interfere with the evaluation (i.e, Psoriasis, Netherton Syndrome)
  • Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00509990

Novartis Investigative Site
Mexico, Mexico
Novartis Investigative Site
Monterrey, Mexico
Novartis Investigative Site
Puebla, Mexico
Novartis Investigative Site
Aragua, Venezuela
Novartis Investigative Site, Edo
Carabobo, Venezuela
Novartis Investigative Site
Caracas, Venezuela
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Chair: Novartis Novartis Pharma AG Basel, Switzerland
  More Information

Additional Information:
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00509990     History of Changes
Other Study ID Numbers: CASM981CVE01
Study First Received: July 31, 2007
Last Updated: March 24, 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Atopic dermatitis, pimecrolimus, children

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017